<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042456</url>
  </required_header>
  <id_info>
    <org_study_id>124.03-2013-GES-0003</org_study_id>
    <nct_id>NCT02042456</nct_id>
  </id_info>
  <brief_title>Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts</brief_title>
  <official_title>Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is investigating whether automated whole breast ultrasound can improve detection
      of cancer in breast cancer screening when used as a supplement to mammography or as a
      supplement to digital breast tomosynthesis
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Change in study staff at the site, change in Sponsor direction
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Abnormal interpretation rate</measure>
    <time_frame>One Year</time_frame>
    <description>Abnormal interpretation rates for each modality (FFDM and DBT+V-Preview, with and without ABUS+V-Preview).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>One Year</time_frame>
    <description>Sensitivity will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>One Year</time_frame>
    <description>Specificity will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Rate</measure>
    <time_frame>One Year</time_frame>
    <description>Cancer Rate will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Predictive Value</measure>
    <time_frame>One Year</time_frame>
    <description>Positive Predictive Value will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>One Year</time_frame>
    <description>Negative Predictive Value will be assessed for each imaging modality: FFDM and DBT+V-Preview, with and without ABUS</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">124</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Main Cohort</arm_group_label>
    <description>Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Digital Breast Tomosynthesis</intervention_name>
    <description>digital breast tomosynthesis technology</description>
    <arm_group_label>Main Cohort</arm_group_label>
    <other_name>GE SenoClaire DBT with V-Preview</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Automated Whole Breast Ultrasound</intervention_name>
    <description>Automated Whole Breast Ultrasound</description>
    <arm_group_label>Main Cohort</arm_group_label>
    <other_name>Invenia ABUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Full Field Digital Mammography</intervention_name>
    <arm_group_label>Main Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be selected from the patients arriving at the clinic for yearly breast cancer
        screening exams
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able and willing to provide signed declaration of informed consent or have a legally
             authorized representative provide signed declaration of informed consent for
             participation in all study procedures;

          -  Women aged â‰¥18 years at the time of enrollment;*

          -  Women with a previous determination of dense breasts determined by mammogram as
             heterogeneously dense or extremely dense;

          -  At moderately increased or high risk (&gt;15% lifetime risk) for breast cancer based on
             meeting one or more of the ACS criteria 1:

        AND Referred for screening mammography

        Exclusion Criteria:

          -  Have been screened using any breast imaging technology in &lt;12 months immediately prior
             to enrollment;

          -  Exhibit breast cancer symptoms according to assessment by the subject's health care
             provider within one year prior to enrollment;

          -  Diagnosed with breast cancer, with or without metastasis, within one year prior to
             enrollment;

          -  Are currently pregnant as determined per standard clinical practice at the
             investigational site;

          -  Present with contraindications to any imaging examination required in the study
             protocol;

          -  Have breast implants; OR

          -  Are lactating.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Washington Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>October 16, 2015</last_update_submitted>
  <last_update_submitted_qc>October 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>dense breasts</keyword>
  <keyword>mammography screening</keyword>
  <keyword>Screening techniques</keyword>
  <keyword>women</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

